Targeted therapy in metastatic renal carcinoma

Jane Mattei; Rodrigo Donalisio da Silva; David Sehrt; Wilson R. Molina; Fernando J. Kim

doi:10.1016/j.canlet.2013.09.038

Targeted therapy in metastatic renal carcinoma

Jane Mattei, Rodrigo Donalisio da Silva, David Sehrt, Wilson R. Molina, Fernando J. Kim

Producción científica: Review article › revisión exhaustiva

36 Citas (Scopus)

Resumen

Background: Advanced renal cell carcinoma is one of the most treatment-resistant malignancies to conventional cytotoxic chemotherapy. The development of new targeted therapy was result of understanding biological pathways underlying renal cell carcinoma. Our objective is to provide an overview of current therapies in metastatic renal cell carcinoma. Methods: MEDLINE/PUBMED was queried in December 2012 to identify abstracts, original and review articles. The research was conducted using the following words: "metastatic renal cell carcinoma" and "target therapy". Phase II and Phase III clinical trials were included followed FDA approval. Total of 40 studies were eligible for review. Conclusion: The result of this review shows benefit of these target drugs in tumor burden, increase progression-free and overall survival and improvement the quality of life compared with previous toxic immunotherapy, although complete response remains rare.

Idioma original	English (US)
Páginas (desde-hasta)	156-160
Número de páginas	5
Publicación	Cancer Letters
Volumen	343
N.º	2
DOI	https://doi.org/10.1016/j.canlet.2013.09.038
Estado	Published - feb 28 2014
Publicado de forma externa	Sí

ASJC Scopus subject areas

Oncology
Cancer Research

Acceder al documento

10.1016/j.canlet.2013.09.038

Otros archivos y enlaces

Citar esto

@article{d90de51da53a43fc8b32015a57ce2937,

title = "Targeted therapy in metastatic renal carcinoma",

abstract = "Background: Advanced renal cell carcinoma is one of the most treatment-resistant malignancies to conventional cytotoxic chemotherapy. The development of new targeted therapy was result of understanding biological pathways underlying renal cell carcinoma. Our objective is to provide an overview of current therapies in metastatic renal cell carcinoma. Methods: MEDLINE/PUBMED was queried in December 2012 to identify abstracts, original and review articles. The research was conducted using the following words: {"}metastatic renal cell carcinoma{"} and {"}target therapy{"}. Phase II and Phase III clinical trials were included followed FDA approval. Total of 40 studies were eligible for review. Conclusion: The result of this review shows benefit of these target drugs in tumor burden, increase progression-free and overall survival and improvement the quality of life compared with previous toxic immunotherapy, although complete response remains rare.",

keywords = "Adjuvant treatment, Metastatic disease, Renal cell carcinoma, Renal tumor, Target therapy",

author = "Jane Mattei and {da Silva}, {Rodrigo Donalisio} and David Sehrt and Molina, {Wilson R.} and Kim, {Fernando J.}",

year = "2014",

month = feb,

day = "28",

doi = "10.1016/j.canlet.2013.09.038",

language = "English (US)",

volume = "343",

pages = "156--160",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Targeted therapy in metastatic renal carcinoma

AU - Mattei, Jane

AU - da Silva, Rodrigo Donalisio

AU - Sehrt, David

AU - Molina, Wilson R.

AU - Kim, Fernando J.

PY - 2014/2/28

Y1 - 2014/2/28

N2 - Background: Advanced renal cell carcinoma is one of the most treatment-resistant malignancies to conventional cytotoxic chemotherapy. The development of new targeted therapy was result of understanding biological pathways underlying renal cell carcinoma. Our objective is to provide an overview of current therapies in metastatic renal cell carcinoma. Methods: MEDLINE/PUBMED was queried in December 2012 to identify abstracts, original and review articles. The research was conducted using the following words: "metastatic renal cell carcinoma" and "target therapy". Phase II and Phase III clinical trials were included followed FDA approval. Total of 40 studies were eligible for review. Conclusion: The result of this review shows benefit of these target drugs in tumor burden, increase progression-free and overall survival and improvement the quality of life compared with previous toxic immunotherapy, although complete response remains rare.

AB - Background: Advanced renal cell carcinoma is one of the most treatment-resistant malignancies to conventional cytotoxic chemotherapy. The development of new targeted therapy was result of understanding biological pathways underlying renal cell carcinoma. Our objective is to provide an overview of current therapies in metastatic renal cell carcinoma. Methods: MEDLINE/PUBMED was queried in December 2012 to identify abstracts, original and review articles. The research was conducted using the following words: "metastatic renal cell carcinoma" and "target therapy". Phase II and Phase III clinical trials were included followed FDA approval. Total of 40 studies were eligible for review. Conclusion: The result of this review shows benefit of these target drugs in tumor burden, increase progression-free and overall survival and improvement the quality of life compared with previous toxic immunotherapy, although complete response remains rare.

KW - Adjuvant treatment

KW - Metastatic disease

KW - Renal cell carcinoma

KW - Renal tumor

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=84891829996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891829996&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2013.09.038

DO - 10.1016/j.canlet.2013.09.038

M3 - Review article

C2 - 24239667

AN - SCOPUS:84891829996

SN - 0304-3835

VL - 343

SP - 156

EP - 160

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -

Targeted therapy in metastatic renal carcinoma

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto